A case of acute hepatocellular and cholestatic liver injury that may have been associated with the use of celecoxib is described. This case was reported to US Food and Drug Administration and the manufacturer of celecoxib.
No takes yet. Share an insight, caveat, or question.
Nachimuthu et al. (2001) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: